Who said this?

"With the real prospects of higher debt levels, of dividends being cut in half, and of revenues of the combined company declining by 17%, this is not a deal which has any meaningful inherent value at this juncture. Moreover, the Pfizer-Wyeth deal is showing a 12% arbitrage return, a telling sign that the chances of the deal not going through are surprisingly high."

Source.